China Biopharmaceutical (01177) announced that the group has established a strategic partnership with Boehringer Ingelheim to...
Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group has established a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative anti-tumor treatments to the mainland China market.
Under the terms of the agreement, the Group and Boehringer Ingelheim will cooperate to jointly develop and commercialize Boehringer Ingelheim's oncology pipeline in mainland China. The strategic partnership covers several of Boehringer Ingelheim's clinical-stage assets, including three clinically-developed assets brigimadlin, Zongertinib, and BI 764532, as well as several early clinical assets. The two sides will work together to bring these oncology products to patients in mainland China. Product revenue will be included in the Group's consolidated financial statements.
According to the announcement, the strategic cooperation will introduce Boehringer Ingelheim's innovative oncology pipeline to enrich the Group's oncology product portfolio and help address unmet clinical needs in China. This strategic cooperation has also expanded the Group's international vision, verified the Group's strong commercialization capabilities, and made the Group the preferred partner for multinational companies.
The oncology sector is the Group's largest treatment area, and the agreement marks the beginning of a strategic partnership between the Group and Boehringer Ingelheim.